Cancer remains a critical concern in global health due to its high prevalence and mortality rates. Despite significant advancements in the development of anti-cancer drugs, drug resistance continues to pose a major challenge in clinical treatments. Drug resistance may be either intrinsic i.e., pre-existent resistance present in the tumor cells even before exposure to chemotherapy, or acquired resistance i.e., induced by drugs during or after treatment of tumors with anticancer compounds. Anti-cancer treatments such as chemotherapy, targeted therapy, and immunotherapy are highly genotype-related interventions. Coding and Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), lncRNAs, circular RNAs (circRNAs), and PIWI-RNA (piRNA) have been shown to play important roles in tumor formation and therapeutic resistance. lncRNAs can activate DNA damage repair, silence tumor suppressor genes, and modulate cancer-related epigenetic changes at the chromatin level in terms of histone modifications, DNA methylation, and altering chromatin architecture.
In recent years, multi-omic analyses have played a pivotal role in unraveling the molecular mechanisms of cancer. Particularly in exploring potential biomarkers for drug resistance, multi-omic approaches offer unique insights. Through comprehensive analysis of the genome, transcriptome, proteome, and metabolome, researchers can gain a deeper understanding of the mechanisms behind cancer cells' resistance to drugs, thereby supporting the development of precision medicine. Meanwhile, exploring the role of the tumor microenvironment (TME) in the development and metastasis of tumors can help us better understand the potential mechanisms of drug resistance in cancer. The aim of this study is to comprehensively explore the application of multi-omics in the study of resistance to anti-cancer drugs, especially in identifying new biomarkers and therapeutic targets.
We cordially invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews with a primary focus on, though not exclusively limited to, the subsequent Subtopics:
• Novel multi-omic methods in detecting biomarkers associated with drug resistance
• Analysis of genetic, epigenetic, transcriptomic, proteomic, and metabolomic changes related to specific anti-cancer drug resistance
• The role of the tumor microenvironment in mediating drug resistance
• Elucidating complex signaling networks and pathways involved in resistance through integrated multi-omic data
• Strategies to overcome drug resistance and enhance the efficacy of existing anti-cancer therapies.
• Strategies for predicting and addressing immunotherapy resistance in cancer
Cancer remains a critical concern in global health due to its high prevalence and mortality rates. Despite significant advancements in the development of anti-cancer drugs, drug resistance continues to pose a major challenge in clinical treatments. Drug resistance may be either intrinsic i.e., pre-existent resistance present in the tumor cells even before exposure to chemotherapy, or acquired resistance i.e., induced by drugs during or after treatment of tumors with anticancer compounds. Anti-cancer treatments such as chemotherapy, targeted therapy, and immunotherapy are highly genotype-related interventions. Coding and Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), lncRNAs, circular RNAs (circRNAs), and PIWI-RNA (piRNA) have been shown to play important roles in tumor formation and therapeutic resistance. lncRNAs can activate DNA damage repair, silence tumor suppressor genes, and modulate cancer-related epigenetic changes at the chromatin level in terms of histone modifications, DNA methylation, and altering chromatin architecture.
In recent years, multi-omic analyses have played a pivotal role in unraveling the molecular mechanisms of cancer. Particularly in exploring potential biomarkers for drug resistance, multi-omic approaches offer unique insights. Through comprehensive analysis of the genome, transcriptome, proteome, and metabolome, researchers can gain a deeper understanding of the mechanisms behind cancer cells' resistance to drugs, thereby supporting the development of precision medicine. Meanwhile, exploring the role of the tumor microenvironment (TME) in the development and metastasis of tumors can help us better understand the potential mechanisms of drug resistance in cancer. The aim of this study is to comprehensively explore the application of multi-omics in the study of resistance to anti-cancer drugs, especially in identifying new biomarkers and therapeutic targets.
We cordially invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews with a primary focus on, though not exclusively limited to, the subsequent Subtopics:
• Novel multi-omic methods in detecting biomarkers associated with drug resistance
• Analysis of genetic, epigenetic, transcriptomic, proteomic, and metabolomic changes related to specific anti-cancer drug resistance
• The role of the tumor microenvironment in mediating drug resistance
• Elucidating complex signaling networks and pathways involved in resistance through integrated multi-omic data
• Strategies to overcome drug resistance and enhance the efficacy of existing anti-cancer therapies.
• Strategies for predicting and addressing immunotherapy resistance in cancer